Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy.

Autor:	Carosielli M; Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy., Carnevali A; Department of Ophthalmology, University Magna Græcia, Catanzaro, Italy., Fallico M; Department of Ophthalmology, University of Catania, Catania, Italy., Pirozzi E; Department of Ophthalmology, Santa Croce e Carle Hospital, Cuneo, Italy., Chiosi F; Department of Ophthalmology, Azienda Ospedaliera dei Colli-Ospedale Monaldi, Naples, Italy., Chronopoulos A; Department of Ophthalmology, Ludwigshafen Hospital, Ludwigshafen am Rhein, Germany., Cucciniello P; Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy., Affatato M; Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy., Rapino G; Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy., dell'Omo R; Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy.
Jazyk:	angličtina
Zdroj:	Translational vision science & technology [Transl Vis Sci Technol] 2023 Dec 01; Vol. 12 (12), pp. 17.
DOI:	10.1167/tvst.12.12.17
Abstrakt:	Purpose: To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy. Methods: Retrospective analysis of 34 eyes treated with intravitreal brolucizumab. Twenty-five eyes (73.5%) had been treated with other anti-vascular endothelial growth factor agents before switching to brolucizumab, whereas nine eyes were naïve. Outcome measures included the change of central foveal thickness and subfoveal choroidal thickness, evaluation of sub/intraretinal fluid on optical coherence tomography, and change in best-corrected visual acuity. Results: Before starting brolucizumab, 23 eyes showed subretinal fluid, 8 both subretinal and intraretinal fluid, and 3 intraretinal fluid only. At the last visit, 22 eyes (64.7%) showed complete reabsorption of both intraretinal and subretinal fluid, whereas subretinal fluid was still present in 8 eyes (23.5%), and both intraretinal and subretinal fluid in 4 eyes (11.8%). The mean number of brolucizumab injections required to achieve complete fluid reabsorption was 2.8 ± 1.8. central foveal thickness decreased from 317.8 ± 109.3 µm to 239.8 ± 74.8 µm (P = 0.0005) and subfoveal choroidal thickness decreased from 399.3 ± 86.2 µm to 355.5 ± 92.7 µm at the end of the follow-up period (P = 0.0008). The mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.4 ± 0.2 to 0.3 ± 0.2 at 1 month after the first injection and remained stable at the same values at the end of the follow-up period (P = 0.04). Conclusions: Intravitreal brolucizumab is effective for the treatment of naïve and recalcitrant pachychoroid neovasculopathy. Translational Relevance: Intravitreal brolucizumab may represent an option in patients with pachychoroid neovasculopathy complicating chronic central serous chorioretinopathy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu